#ESMO25: New evidence presented for #ADCs moving into the curative setting in #BreastCancer and #BladderCancer. Paolo Tarantino discusses the ‘unleashing’ of neoadjuvant and adjuvant ADC therapy to reduce recurrence and save lives
#ESMODailyReporter ➡️ https://ow.ly/vWqe50XeuTe

Paolo Tarantino, MD

“RWE offers practical insights and guidance but can’t replace prospective, randomised trials. Rigour is key to refining frontline strategies.” Michiel S. Van der Heijden

#ESMO25 #BladderCancer #OncSky #MedSky #MedEd

For some #BladderCancer patients, TMT can be a valid alternative to radical cystectomy, but patient selection is critical. Patrizia Giannatempo at #ESMO25 highlights the importance of personalised approaches.

#Oncology #OncSky #MedSky #MedEd

#ESMO25: Peri-operative enfortumab vedotin plus pembrolizumab significantly prolonged event-free and overall survival in cisplatin-ineligible patients with muscle-invasive #BladderCancer in the phase III KEYNOTE-905/EV-303 trial
#ESMODailyReporter➡️httpsef="https://ow.ly/YVy550XeuKH" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://ow.ly/YVy550XeuKH

Karima Oualla highlights that ctDNA is emerging as a highly prognostic tool in #BladderCancer and may help guide adjuvant therapy decisions. It’s a glimpse of precision oncology in action.

#ESMO25 #Oncology #OncSky #MedSky #MedEd

“Response to neoadjuvant therapy has prognostic value, offers hints about tumour biology and enables risk stratification for adjuvant therapy.” Petros Grivas

A step toward personalised #BladderCancer care.

#ESMO25 #Oncology #OncSky #MedSky #MedEd

PADCEV™ Plus KEYTRUDA™: A New Hope for Bladder Cancer Patients as Trials Show Promising Results#Japan#Tokyo#KEYTRUDA#PADCEV#BladderCancer

Join us as we bring you the real-time updates you need to know on optimising management of localised bladder cancer from #ESMO25. From new strategies and the latest trials to treatment pathways, stay tuned for LIVE expert insights

#Oncology #OncSky #MedSky #MedEd #BladderCancer

Dear Colleagues at #ESMO25
A Great pleasure to Introduce our Faculty Dr. Petros Grivas 🇺🇸 from Fred Hutch who talks to us about all of the Exciting #BladderCancer Science being Presented in Berlin

✅ Keynote 905
✅ Disitamab vedotin (DV) plus toripalimab
✅ IMvigor011
And much more

Oncology experts will be joining our friends and collaborators at COR2ED in Berlin for #ESMO25
Coming Soon👉 cor2ed.com/esmo-2025/up...

They will share their insights on the latest data on #BladderCancer #KidneyCancer #ProstateCancer #LungCancer #BreastCancer #GynOnc and Upper GI Cancers

Sign up

Lots of exciting data at #ESMO25. Here are the 3 Presidential Symposia presentations. Tomorrow: DESTINY-Breast11 (high-risk HER2+ eBC), DESTINY-Breast05 (high-risk HER2+), KEYNOTE-05 (MIBC), KEYNOTE-B96 (ovarian). #BCSM #Bladdercancer #gusm #ovariancancer #gynsm

Don't miss the first presidential symposium at #ESMO25! Tomorrow, join @DrRosenbergMSK to hear his thoughts on a study of perioperative enfortumab vedotin plus pembrolizumab in participants with muscle-invasive #bladdercancer. @mskcancercenter.bsky.social

Learn more: bit.ly/42JM3ws

Could new data from #ESMO25 reshape the future of non-muscle-invasive bladder cancer care? Get the updates you need to know from this year’s congress with on-demand coverage on Medthority #MedSky #NMIBC #BladderCancer #OncSky

ow.ly/yY5k50XehYn

Mutations that give certain cells an evolutionary advantage may help explain why men are more likely than women and smokers are more likely than nonsmokers to develop #BladderCancer, according to a study by the Risques lab at @uwmedicine.bsky.social.

Learn more: https://bit.ly/3Jd8Nye

🔗 Read more: bit.ly/ONCOnews17O-3

#ONCOnews #OncoAlert #OncEd #Phase3Update #BladderCancer #ESMO2025 #CancerTreatment

Welcome to #ESMO25 : The OncoAlert #GUCancer Faculty, led by Dr. Natalia Gandur🇦🇷 , Dr. Regina Barragan🇲🇽 & Dr. Gil Morgan🇺🇸 have selected the OncoAlert TOP 🔟 #ESMO25 Abstracts In #ProstateCancer, #KidneyCancer #BladderCancer and #PenisCancer to be presented in Berlin🇩🇪 Picked using a Delphi System

#bladdercancerlife #bladdercancer #bladdercancerwarrior #bcgtreatment #fightcancer

Read our latest issue: bit.ly/3KTVjrC

#Antiviral #AlopeciaAreata #BladderCancer

🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TNhXS7 !

#Oncology #SocialListening #LucidQuest

The FDA Approval of TAR-200 Represents Potential Bladder-Sparing Option in BCG-Unresponsive #NMIBC #BladderCancer #Oncology

www.onclive.com/view/fda-app...

These data slides from the World Bladder Cancer Patient Coalition give some stark numbers about the challenges women with bladder cancer face. Have you faced any of these challenges on your journey to diagnosis and care? #bladdercancer #bladdercancerwarrior #womenshealth #fightcancer

Breast, Lung & Bladder Cancer Breakthroughs! Dana-Farber researchers unveil major Phase 3 trial results at #ESMO2025 — revealing powerful new findings across multiple cancers.
#TCSC #Oncology #DanaFarber #BreastCancer #LungCancer #BladderCancer #CancerTreatment

www.dana-farber.org/newsroom/new...

Cystoscopy results #bladdercancer #cystoscopy #scanxiety #fightcancer #cancersucks

Success Rate of Immunotherapy for Bladder Cancer. What Patients Need to Know in 2025

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Immunotherapy #BladderCancer #SuccessRate

Cystoscopy tomorrow got me like! 😱😱😱 #fightcancer #bladdercancer #scanxiety #cystoscopy #anxiety